MANTRA: Milademetan for the Treatment of Patients With Dedifferentiated (DD) Liposarcoma (LPS)
MANTRA is an ongoing Phase 3 study of milademetan in patients with DD LPS who have progressed on prior therapy.
- Patients with DD LPS with or without a well-differentiated component
- ≥1 Prior systemic treatment, including at least 1 prior anthracycline
- Treatment until PD or intolerability
- PFS (Primary): Approximately 105 events by blinded central review to trigger primary analysis
- OS, ORR, DCR, DOR
*With or without a well-differentiated component.
DCR, disease control rate; DOR, duration of response; IV, intravenous; ORR, objective response rate; OS, overall survival; PD, progressive disease; PFS, progression-free survival; QD 3/14, once daily on days 1-3 every 14 days; Q3W, every 3 weeks.